Test Code APRI Prolonged Clot Time Profile Interpretation
Specimen Required
Useful For
Interpretation of testing performed as part of a profile to determine the cause of prolongation of prothrombin time or activated partial thromboplastin time
Interpretation of testing performed as part of a profile for screening for prolonged clotting times and determining the presence of factor deficiencies or inhibitor (eg, factor-specific, lupus-like, or the presence of heparin)
Method Name
Only orderable as part of a profile. For more information see APROL / Prolonged Clot Time Profile, Plasma.
Medical Interpretation
Reporting Name
Prolonged Clot Time Prof InterpSpecimen Type
Plasma Na CitSpecimen Stability Information
Specimen Type | Temperature | Time | Special Container |
---|---|---|---|
Plasma Na Cit | Frozen | 14 days |
Reject Due To
Gross hemolysis | Reject |
Gross lipemia | Reject |
Gross icterus | Reject |
Clinical Information
When coagulation screening tests are performed to verify normal function of the coagulation system (eg, preoperative, routine examination), they sometimes indicate an abnormality that may be unexplained (ie, prolonged clotting times). This consultation provides validation of the prolongation and as comprehensive a workup as needed to define the abnormality.
Possibilities for a cause of prolongation include:
-Artifactual due to high hematocrit (dilution of specimen by anticoagulant if patient hematocrit is 55% or greater)
-Factor deficiencies, congenital or acquired
-Factor inhibitors eg, factor VIII inhibitors (bleeding disorder)
-Lupus anticoagulant (risk for thrombosis or recurrent miscarriage)
-Anticoagulant drug effect eg, (including warfarin [Coumadin or Jantoven], oral anti-Xa inhibitors, oral direct thrombin inhibitors), heparin.
Reference Values
Only orderable as part of a profile. For more information see APROL / Prolonged Clot Time Profile, Plasma.
An interpretive report will be provided.
Interpretation
An interpretive report will be provided when testing is completed, noting a presence or absence of a prolonged bleeding disease state.
Cautions
If the patient's hematocrit is 55% or greater, the volume of citrate anticoagulant should be adjusted prior to submitting the specimen for analysis to avoid dilution of plasma by anticoagulant.(1)
For optimal results, the patient should not be receiving oral vitamin K inhibitor (eg, warfarin, Coumadin), heparin, low-molecular weight heparin, hirudin (Refludan), argatroban, or fibrinolytic agents (eg, streptokinase, tissue plasminogen activator). If necessary, testing may be performed on patients receiving these treatments. Medications affecting coagulation parameters must be noted on requisition for accurate interpretation of results.
If patient has been recently transfused or will be, it is best to perform this study pretransfusion, if possible.
Method Description
A coagulation expert (clinician or hematopathologist) reviews the laboratory data and an interpretive report is issued.
Day(s) Performed
Monday through Friday
Report Available
3 to 7 daysPerforming Laboratory
Mayo Clinic Laboratories in RochesterTest Classification
Not ApplicableCPT Code Information
85390-26 Special Coagulation Interpretation
LOINC Code Information
Test ID | Test Order Name | Order LOINC Value |
---|---|---|
APRI | Prolonged Clot Time Prof Interp | 69049-5 |
Result ID | Test Result Name | Result LOINC Value |
---|---|---|
603324 | Reviewed by | 18771-6 |
603183 | Prolonged Clot Time Prof Interp | 69049-5 |